chlorpropamide has been researched along with Demyelinating Diseases in 1 studies
Chlorpropamide: A sulfonylurea hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. (From Martindale, The Extra Pharmacopoeia, 30th ed, p277)
chlorpropamide : An N-sulfonylurea that is urea in which a hydrogen attached to one of the nitrogens is substituted by 4-chlorobenzenesulfonyl group and a hydrogen attached to the other nitrogen is substituted by propyl group. Chlorpropamide is a hypoglycaemic agent used in the treatment of type 2 (non-insulin-dependent) diabetes mellitus not responding to dietary modification.
Demyelinating Diseases: Diseases characterized by loss or dysfunction of myelin in the central or peripheral nervous system.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chlorpropamide (CPM) has been reported to produce impaired water excretion due to the enhancement of renal vasopressin (ADH) action and/or due to centrally enhanced ADH release, but it is still unknown whether CPM gives rise to ADH release with a subsequent hyponatremia in diabetes mellitus (DM), which, in turn, causes an impairment of the central nervous system." | 7.69 | Chlorpropamide-induced ADH release, hyponatremia and central pontine myelinolysis in diabetes mellitus. ( Funyu, T; Kimura, T; Mori, T; Ohta, M; Ota, K; Sahata, T; Sato, K; Shoji, M; Sugimura, K; Yamamoto, T, 1995) |
| "Chlorpropamide (CPM) has been reported to produce impaired water excretion due to the enhancement of renal vasopressin (ADH) action and/or due to centrally enhanced ADH release, but it is still unknown whether CPM gives rise to ADH release with a subsequent hyponatremia in diabetes mellitus (DM), which, in turn, causes an impairment of the central nervous system." | 3.69 | Chlorpropamide-induced ADH release, hyponatremia and central pontine myelinolysis in diabetes mellitus. ( Funyu, T; Kimura, T; Mori, T; Ohta, M; Ota, K; Sahata, T; Sato, K; Shoji, M; Sugimura, K; Yamamoto, T, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kimura, T | 1 |
| Ota, K | 1 |
| Shoji, M | 1 |
| Funyu, T | 1 |
| Ohta, M | 1 |
| Sato, K | 1 |
| Yamamoto, T | 1 |
| Mori, T | 1 |
| Sahata, T | 1 |
| Sugimura, K | 1 |
1 other study available for chlorpropamide and Demyelinating Diseases
| Article | Year |
|---|---|
Chlorpropamide-induced ADH release, hyponatremia and central pontine myelinolysis in diabetes mellitus.
Topics: Aged; Chlorpropamide; Demyelinating Diseases; Diabetes Complications; Diabetes Mellitus; Female; Hum | 1995 |